Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11863358 | 0.87 | CYP2A6 (0.32) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9064838 | 0.83 | CALM1 (0.38) | CALM1ALOX5BCL2BCL2L1CYP1A2 | |
| SCHEMBL6740961 | 0.82 | KCNH2 (0.39) | LOXL2 | |
| SCHEMBL10691711 | 0.81 | CYP11B1 (0.41) | CYP1A2CYP2D6LTA4H | |
| SCHEMBL3143306 | 0.80 | HPRT1 (0.42) | CALM1GPR55 | |
| SCHEMBL9466571 | 0.75 | TRPA1 (0.32) | — | |
| SCHEMBL6674217 | 0.75 | TRPA1 (0.32) | — | |
| SCHEMBL66086 | 0.75 | CYP1A2 (0.39) | CYP1A2 | |
| SCHEMBL6897074 | 0.75 | LOXL2 (0.37) | LOXL2 | |
| SCHEMBL4271458 | 0.75 | TSHR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115364079-A | Application of benzyl naphthyl (sulfoxide) sulfone compound in preparing radioprotective medicament | 中国人民解放军军事科学院军事医学研究院 | 2022-11-22 | — | — | CN | claimed |
| EP-3352991-A1 | HEAT-SENSITIVE RECORDING MATERIAL | Mitsubishi HiTec Paper Europe GmbH (DE) | 2018-08-01 | — | — | EP | claimed |
| EP-3101018-A1 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma L.P. (US) | 2016-12-07 | — | — | EP | claimed |
| US-20160272640-A1 | SUBSTITUTED PIPERIDIN-4-AMINO-TYPE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2016-09-22 | — | — | US | claimed |
| EP-3019477-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | Novartis AG (CH) | 2016-05-18 | — | — | EP | claimed |
| US-20160002203-A1 | QUINAZOLIN-4(3H)-ONE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | TADESSE DAWIT (US) | 2016-01-07 | — | — | US | claimed |
| US-20150238485-A1 | OXIME-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AS ORL-1 MODULATORS | SHIONOGI & CO., LTD. (JP) | 2015-08-27 | — | — | US | claimed |
| US-9040533-B2 | Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators | PURDUE PHARMA L.P. (US) | 2015-05-26 | — | — | US | claimed |
| WO-2015003223-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-01-15 | — | — | WO | claimed |
| US-8846929-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2014-09-30 | — | — | US | claimed |
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | claimed |
| EP-2086958-A2 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma LP (US) | 2009-08-12 | — | — | EP | claimed |
| EP-2043634-A2 | SUBSTITUTED PYRAZOLES AS GHRELIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2009027820-A2 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (DE) | 2009-03-05 | — | — | WO | claimed |
| US-20080269295-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2008-10-30 | — | — | US | claimed |
| WO-2008008286-A2 | SUBSTITUTED PYRAZOLES AS GHRELIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-01-17 | — | — | WO | claimed |
| EP-1361876-A4 | NOVEL CANNABIMIMETIC LIGANDS | UNIV CONNECTICUT (US) | 2004-03-31 | — | — | EP | claimed |
| EP-1361876-A2 | NOVEL CANNABIMIMETIC LIGANDS | The University of Connecticut (US) | 2003-11-19 | — | — | EP | claimed |
| WO-2002058636-A2 | NOVEL CANNABIMIMETIC LIGANDS | UNIVERSITY OF CONNECTICUT (US) | 2002-08-01 | — | — | WO | claimed |
| EP-0101954-B1 | ISOINDOLAZINES, PROCESS FOR THEIR PREPARATION AND THEIR USE | BAYER AG (DE) | 1986-07-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238485-A1 | OXIME-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AS ORL-1 MODULATORS | OPRL1, OGFRL1, OPRD1 | CALM1 249/4885LOXL2 25/4885ALOX5 318/4885 |
| US-20160272640-A1 | SUBSTITUTED PIPERIDIN-4-AMINO-TYPE COMPOUNDS AND USES THEREOF | OPRD1, OPRL1, P2RX4 | CALM1 1207/4885LOXL2 2357/4885ALOX5 1511/4885 |
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | GIPR, GPR119, GLP1R | CALM1 3650/4885LOXL2 4645/4885ALOX5 2997/4885 |
| US-20080269295-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | TPMT, ABCB1, FDPS | CALM1 2542/4885LOXL2 3245/4885ALOX5 2493/4885 |
| US-20160002203-A1 | QUINAZOLIN-4(3H)-ONE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | OPRK1, OPRD1, P2RX4 | CALM1 819/4885LOXL2 4070/4885ALOX5 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.